| Popis: |
The availability of highly potent human immunodeficiency virus (HIV)-1- protease inhibitors has revolutionized both our ability to treat people infected with HIV-1 and our view of how to use antiretroviral agents. Some clinical benefit was obtained with the less potent nucleoside analogs, but resistance almost always appeared and clinical progression resumed. With the availability of potent protease-inhibitor therapies, it has become possible to suppress virus replication to undetectable levels of viral RNA in blood plasma (virus load). However, strong therapy that does not achieve suppression leads to resistance, even to the potent protease inhibitors. Thus, the goal of therapy is to combine drugs so that the total potency is sufficient to suppress detectable virus. |
